<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Progestins" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Progestins</book-part-id>
      <title-group>
        <title>Progestins</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>6</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Prochlorperazine" document-type="chapter">Prochlorperazine</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Proguanil" document-type="chapter">Proguanil</related-object>
    </book-part-meta>
    <body>
      <p>Desogestrel, Dydrogesterone, Levonorgestrel, Medroxyprogesterone, Megestrol, Norethindrone, Norgestrel, Norgestimate, Progesterone</p>
      <sec id="Progestins.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Progestins.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Progesterone is the naturally occurring hormone that is actively secreted by the ovary and interacts with progesterone receptors in the reproductive tract, mammary gland and central nervous system. Progesterone and the progestins have been used alone or in combination with estrogens in oral contraceptives, as therapy of postmenopausal symptoms, for secondary amenorrhea, abnormal uterine bleeding, endometriosis and progesterone sensitive cancers. High doses of progestins can cause liver test abnormalities and can occasionally lead to clinical apparent acute liver injury.</p>
        </sec>
        <sec id="Progestins.Background">
          <title>Background</title>
          <p>Progesterone (proe jes' ter one) is the naturally occurring progestin which is secreted by the ovary and has a multitude of actions on many organs, but predominantly on the reproductive tract, mammary glands and central nervous system. Large amounts of progesterone are produced in women by the corpus luteum during the second half of the menstrual cycle, which inhibits the effects of estrogen on endometrial proliferation and results in a secretory status of the endometrium in preparation for implantation of a fertilized egg. If pregnancy does not occur, the corpus luteum regresses and levels of progesterone fall, triggering menstruation and resetting of the ovarian cycle. Progesterone also affects mammary glands and is required for their development and maintenance and, in the central nervous system, increases body temperature and ventilator responses. Progesterone also has androgenic and antiestrogenic effects and causes an increase in basal insulin levels, enhances fat deposition and decreases bone turnover. Modifications of the progesterone molecule can produce compounds with better absorption and pharmacokinetics and more focused and specific activities.</p>
          <p>Progestins are compounds with biological activities similar to progesterone. Progestins developed for clinical use include desogestrel, dydrogesterone, levonorgestrel, medroxyprogesterone, megestrol, 19-nortestosterone, norethindrone, norgestrel and norgestimate, among others. Many of these progestins are used in combination with estrogens in oral contraceptives. In addition, some are used alone as contraceptive agents and to treat secondary amenorrhea, abnormal uterine bleeding, endometriosis, infertility and premature labor. Progestins have also been used to treat progesterone sensitive cancers (endometrial, renal, breast), and as therapy of anorexia and cachexia due to cancer chemotherapy or the acquired immunodeficiency syndrome (AIDS). Progestins used without estrogens include (with common brand names and year of approval in the United States): medroxyprogesterone (Provera and others: 1959), megestrol (Megase: 1971) and norethindrone (Camila, Errin, Micronor, Aygestin: 1973). Common side effects of progestin therapies include nausea, headaches, anxiety, weight gain, edema and breast tenderness and engorgement.</p>
        </sec>
        <sec id="Progestins.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>High doses of progestins can cause liver enzyme elevations that generally rise after 1 to 2 weeks of treatment and consist largely of serum aminotransferase elevations without changes in alkaline phosphatase or bilirubin. These abnormalities are generally short lived and resolve rapidly with dose modification or discontinuation. These elevations may be more frequent when progestins are administered with high doses of estrogens or tamoxifen. Isolated case reports of symptoms with serum aminotransferase elevations and even jaundice during progestin therapy have been published, but the relationship to the hormonal therapy has not always been clear. In some instances, the liver injury was attributed to a progestin releasing intrauterine device (IUD). Finally, rare instances of cholestasis with bland hepatic injury that is typical of estrogen induced liver injury have been reported with use of progestins alone. The fact that progesterone derivatives can be metabolized to estrogenic compounds makes it possible that these cases of cholestatic jaundice are actually due to estrogens rather than the progestin molecules.</p>
          <p>Likelihood score: A (well established cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Progestins.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which progesterone therapy leads to liver injury is not known. Semi-synthetic progesterones may be metabolized to estrogenic compounds that might be responsible for the rare instances of cholestatic jaundice reported with progesterone only therapy.</p>
        </sec>
        <sec id="Progestins.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The rare instances of liver injury reported during progestin therapy have invariably been self-limiting and have resolved completely with stopping the progesterone preparation. Clearly documented fatal cases have not been published. Cross sensitivity to estrogen therapy has not been demonstrated in patients developing jaundice during progesterone therapy, but might be expected.</p>
          <p>References to the safety and hepatic injury associated with progesterone and the progestins are given together after this introductory section. The safety and hepatic injury due to estrogenic agents and estrogen containing birth control pills are described in the overview section on Estrogens and Oral Contraceptives.</p>
          <p>Drug Class: Obstetrical and Gynecological Agents; Hormonal Agents</p>
        </sec>
      </sec>
      <sec id="Progestins.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Medroxyprogesterone &#x02013; Generic, Provera&#x000ae; [Oral], Depo-Provera&#x000ae; [Injection]</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Hormonal Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Progestins">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Progestins.CHEMICAL_FORMULAS_AND_STRUCTU">
        <title>CHEMICAL FORMULAS AND STRUCTURES</title>
        <table-wrap id="Progestins.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">CAS REGISTRY<break/>NO.</th>
                <th id="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">MOLECULAR<break/>FORMULA</th>
                <th id="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Progesterone</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134971194">57-83-0</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H30-O2</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134971194" document-id-type="sid" document-type="summary" object-id="134971194" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Desogestrel</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135003936">54024-22-5</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C22-H30-O</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135003936" document-id-type="sid" document-type="summary" object-id="135003936" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Dydrogesterone</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134973758">152-62-5</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H28-O2</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134973758" document-id-type="sid" document-type="summary" object-id="134973758" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Levonorgestrel</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134976459">797-63-7</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H28-O2</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134976459" document-id-type="sid" document-type="summary" object-id="134976459" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medroxyprogesterone</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134977029">520-85-4</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C22-H32-O3</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134977029" document-id-type="sid" document-type="summary" object-id="134977029" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Megestrol</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134984412">3562-63-8</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C22-H20-O3<break/> C22-H30-O3</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134984412" document-id-type="sid" document-type="summary" object-id="134984412" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Norethindrone</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134971047">68-22-4</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C20-H26-O2</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134971047" document-id-type="sid" document-type="summary" object-id="134971047" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Norgestrel</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134987052">6533-00-2</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H28-O2</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134987052" document-id-type="sid" document-type="summary" object-id="134987052" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_Progestins.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Norgestimate</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135000359">35189-28-7</ext-link>
                </td>
                <td headers="hd_h_Progestins.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C23-H31-N-O3</td>
                <td headers="hd_h_Progestins.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135000359" document-id-type="sid" document-type="summary" object-id="135000359" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Progestins.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 01 June 2020</p>
        <p>Abbreviations: OCC, oral contraceptive; IUD, intrauterine device.</p>
        <ref-list id="Progestins.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Progestins.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hormonal derivatives and related drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 555-88.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; while progesterone has no demonstrable adverse effects on hepatic function, synthetic progestins have been linked to cases of cholestatic jaundice, particularly when used in higher than contraceptive doses).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Progestins.REF.chitturi.2007">
            <mixed-citation publication-type="book">Chitturi S, Farrell GC. Adverse effects of hormones and hormone antagonists on the liver. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd ed. New York: Informa Healthcare USA, 2007, pp. 707-22.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of female sex hormones published in 2007 states that progestin-only contraceptives or high dose progestin regimens used in breast cancer may rarely produce cholestasis).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Progestins.REF.levin.2018">
            <mixed-citation publication-type="book">Levin ER, Vitek WS, Hammes SR. Progestins: Estrogens, progestins and the female reproductive tract. In, Brunton LL, Hilal-Dandan R, Knollman B, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 803-32.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Progestins.REF.perezmera.1962.1137">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Perez-Mera</surname>
                  <given-names>RA</given-names>
                </name>
                <name name-style="western">
                  <surname>Shields</surname>
                  <given-names>CE</given-names>
                </name>
              </person-group>
              <article-title>Jaundice associated with norethindrone acetate therapy.</article-title>
              <source>N Engl J Med</source>
              <year>1962</year>
              <volume>267</volume>
              <fpage>1137</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(35 year old woman developed jaundice 1 year after starting norethindrone and shortly after dose escalation [bilirubin 6.5 mg/dL], liver biopsy showing cholestasis, resolving after stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">13942388</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.routier.1967.229">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Routier</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Corette</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Dannas</surname>
                  <given-names>P.</given-names>
                </name>
              </person-group>
              <comment>[Severe hepatitis and synthetic progestins]</comment>
              <source>J Sc Med Lille</source>
              <year>1967</year>
              <volume>85</volume>
              <fpage>229</fpage>
              <lpage>34</lpage>
              <pub-id pub-id-type="pmid">5619096</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.werner.1969.186">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Werner</surname>
                  <given-names>T.</given-names>
                </name>
              </person-group>
              <comment>[Jaundice with blockage after therapy with norethisterone acetate]</comment>
              <source>Z Gastroenterol</source>
              <year>1969</year>
              <volume>7</volume>
              <fpage>186</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(63 year old woman with metastatic breast cancer developed jaundice 7 weeks after starting high doses of norethisterone [bilirubin 10.4 mg/dL, ALT 33 IE, Alk P 2 times ULN], liver biopsy showing bland cholestasis, resolving slowly within 4 months of stopping).</italic>
                </p>
              </annotation>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.adlercreutz.1970.630">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Adlercreutz</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Tenhunen</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>Some aspects of the interaction between natural and synthetic female sex hormones and the liver.</article-title>
              <source>Am J Med</source>
              <year>1970</year>
              <volume>49</volume>
              <fpage>630</fpage>
              <lpage>48</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the hepatic effects of synthetic estrogens and progestins states that "intrahepatic cholestasis and jaundice... have been reported only for progestogens with the 19-norsteroid configuration").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4924590</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.metreau.1972.318">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Metreau</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Dhumeaux</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Berthelot</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <article-title>Oral contraceptives and the liver.</article-title>
              <source>Digestion</source>
              <year>1972</year>
              <volume>7</volume>
              <fpage>318</fpage>
              <lpage>35</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the hepatic effects of oral contraceptives).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4602326</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.langlands.1975.584">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Langlands</surname>
                  <given-names>AO</given-names>
                </name>
                <name name-style="western">
                  <surname>Martin</surname>
                  <given-names>WM</given-names>
                </name>
              </person-group>
              <article-title>Jaundice associated with norethisterone-acetate treatment of breast cancer.</article-title>
              <source>Lancet</source>
              <year>1975</year>
              <volume>1</volume>
              <issue>7906</issue>
              <fpage>584</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 107 patients with advanced breast cancer treated with norethisterone, 6 developed jaundice after 6-57 weeks of treatment [bilirubin 1.8-7.6 mg/dL, ALT 192-287 U/L, Alk P 12-80 KAU], resolving after stopping; literature review suggests that jaundice arises in 2-3% of progesterone treated patients).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">47070</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.kreek.1987.8">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kreek</surname>
                  <given-names>MJ</given-names>
                </name>
              </person-group>
              <article-title>Female sex steroids and cholestasis.</article-title>
              <source>Semin Liver Dis</source>
              <year>1987</year>
              <volume>7</volume>
              <fpage>8</fpage>
              <lpage>23</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of cholestasis of pregnancy and estrogens: "many synthetic progestins are metabolized to estrogenic compounds").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3296217</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.meijers.1986.1121">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Meijers</surname>
                  <given-names>WH</given-names>
                </name>
                <name name-style="western">
                  <surname>Willemse</surname>
                  <given-names>PHB</given-names>
                </name>
                <name name-style="western">
                  <surname>Sleijfer</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Mulder</surname>
                  <given-names>NH</given-names>
                </name>
                <name name-style="western">
                  <surname>Grond</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Hepatocellular damage by cyproterone acetate.</article-title>
              <source>Eur J Cancer Clin Oncol</source>
              <year>1986</year>
              <volume>22</volume>
              <fpage>1121</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 20 women with advanced breast cancer treated with cyproterone [an antiandrogen with progestative effects], 3 developed serum enzyme elevations at least 10 times ULN [GGT and AST] after 12 weeks, which resolved rapidly upon stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2946585</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.riippa.1984.109">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Riippa</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Kauppila</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Sundstr&#x000f6;, Vihko R. Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma.</article-title>
              <source>Anticancer Res</source>
              <year>1984</year>
              <volume>4</volume>
              <fpage>109</fpage>
              <lpage>12</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a trial of the combination of tamoxifen and high doses of medroxyprogesterone, 4 of 30 patients developed marked increases in ALT [80-600 IU/L] within 1-3 months, resolving within 1-2 months of stopping without jaundice and with minimal symptoms).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6235770</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.foitl.1989.438">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Foitl</surname>
                  <given-names>DR</given-names>
                </name>
                <name name-style="western">
                  <surname>Hyman</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Lefkowitch</surname>
                  <given-names>JH</given-names>
                </name>
              </person-group>
              <article-title>Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer.</article-title>
              <source>Cancer</source>
              <year>1989</year>
              <volume>63</volume>
              <fpage>438</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Woman with metastatic breast cancer was treated with high doses of megestrol [800-1200 mg/day] intermittently and presented 1 month later with liver test abnormalities [bilirubin 1.0 rising to 11.2 mg/dL, ALT 160 U/L, Alk P 324 U/L], with fluctuating levels of bilirubin and fever until her death 26 days after admission).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2912522</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.hannaford.1997.145">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hannaford</surname>
                  <given-names>PC</given-names>
                </name>
                <name name-style="western">
                  <surname>Kay</surname>
                  <given-names>CR</given-names>
                </name>
                <name name-style="western">
                  <surname>Vessey</surname>
                  <given-names>MP</given-names>
                </name>
                <name name-style="western">
                  <surname>Painter</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Mant</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Combined oral contraceptives and liver disease.</article-title>
              <source>Contraception</source>
              <year>1997</year>
              <volume>55</volume>
              <fpage>145</fpage>
              <lpage>51</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of two large prospective studies of OCC use from the UK [&#x0003e;200,000 women-years] found low rate of liver disease and no association with OCC use; in one study, a possible increased risk for mild liver disease during first 4 years of use ).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9115002</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.altinta_.2004.49">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Altinta&#x0015f;</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>O&#x0011f;uz</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Ka&#x000e7;ar</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Ozderin</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Sezgin</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Zengin</surname>
                  <given-names>NI</given-names>
                </name>
              </person-group>
              <article-title>Dydrogesterone-induced hepatitis and autoimmune hemolytic anemia.</article-title>
              <source>Turk J Gastroenterol</source>
              <year>2004</year>
              <volume>15</volume>
              <fpage>49</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(26 year old woman had recurrent episodes of hepatitis occurring after taking dydrogesterone for 18 and 15 days [bilirubin 31 rising to 51.1 mg/dL, ALT 204 to 704 U/L, Alk P 144, ANA 1:40], resolving within 1 month of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15264122</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.anand.2005.232">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Anand</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Gorard</surname>
                  <given-names>DA</given-names>
                </name>
              </person-group>
              <article-title>Norethisterone-induced cholestasis.</article-title>
              <source>QJM</source>
              <year>2005</year>
              <volume>98</volume>
              <fpage>232</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Two cases of cholestatic jaundice during norethisterone therapy: 18 and 34 year old women on norethisterone for 2 weeks and 2 years developed jaundice and itching [bilirubin 2.5 and 1.9 mg/dL, ALT 540 and 179, Alk P 102 and 532 U/L], with recovery after stopping, one treated with prednisone).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15728406</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.faddah.2005.1145">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Faddah</surname>
                  <given-names>LM</given-names>
                </name>
                <name name-style="western">
                  <surname>Al-Rehany</surname>
                  <given-names>MA</given-names>
                </name>
                <name name-style="western">
                  <surname>Abdel-Hamid</surname>
                  <given-names>NM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bakeet</surname>
                  <given-names>AA</given-names>
                </name>
              </person-group>
              <article-title>Oxidative stress, lipid profile and liver functions in average Egyptian long term depo medroxy progesterone acetate (DMPA) users.</article-title>
              <source>Molecules</source>
              <year>2005</year>
              <volume>10</volume>
              <fpage>1145</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 80 women on medroxyprogesterone [given by depo injection every 3 months] for 1-4 years, there were no consistent differences in mean ALT [15-20 U/L], Alk P [64-71 U/L] or bilirubin [0.49-0.54 mg/dL] levels compared to controls).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18007380</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.molinari.2006.1892">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Molinari</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Watt</surname>
                  <given-names>KD</given-names>
                </name>
                <name name-style="western">
                  <surname>Kruszyna</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Nelson</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Walsh</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>WY</given-names>
                </name>
                <name name-style="western">
                  <surname>Nashan</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Peltekian</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Acute liver failure induced by green tea extracts: case report and review of the literature.</article-title>
              <source>Liver Transpl</source>
              <year>2006</year>
              <volume>12</volume>
              <fpage>1892</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(44 year old woman developed jaundice 4 months after starting green tea extract [720 mg/day] for weight loss [bilirubin 13.1 rising to 43.2 mg/dL, ALT 3583 U/L, GGT 112 U/L], undergoing liver transplantation 17 days after admission; patient was also on progesterone injections for contraception).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17133573</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.jimenezsaenz.2007.1067">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jimenez-Saenz</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Martinez-Sanchez</surname>
                  <given-names>C</given-names>
                </name>
              </person-group>
              <article-title>Green tea extracts and acute liver failure: the need for caution in their use and diagnostic assessment.</article-title>
              <source>Liver Transpl</source>
              <year>2007</year>
              <volume>13</volume>
              <fpage>1067</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Letter in response to Molinari [2006] indicating that progesterone may have contributed to the injury and describing a 22 year old woman who developed jaundice 2 weeks after starting progesterone [bilirubin 13.5 mg/dL ALT 1584 U/L], with resolution on stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17600357</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.ushijima.2007.2798">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ushijima</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Yahata</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Yoshikawa</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Konishi</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Yasugi</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Saito</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Nakanishi</surname>
                  <given-names>T</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.</article-title>
              <source>J Clin Oncol</source>
              <year>2007</year>
              <volume>25</volume>
              <fpage>2798</fpage>
              <lpage>803</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 45 women with endometrial hyperplasia or carcinoma treated with medroxyprogesterone for up to 3 years, 5 developed liver enzyme elevations, but few details provided).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17602085</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.bigrigg.1999.69">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bigrigg</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Evans</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Gbolade</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Newton</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Pollard</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Szarewski</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Thomas</surname>
                  <given-names>C</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Depo Provera. Position paper on clinical use, effectiveness and side effects.</article-title>
              <source>Br J Fam Plann</source>
              <year>1999</year>
              <volume>25</volume>
              <fpage>69</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Expert review of medroxyprogesterone given im every 12 weeks as a form of progesterone only birth control claims that it is "the most effective reversible contraceptive available" and that major side effects are menstrual irregularity [70%], weight gain [in 70%, averaging 2 kg per year] and mood changes; no mention of hepatotoxicity or jaundice).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">10454658</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.tuomikoski.2008.375.e1">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tuomikoski</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Aittom&#x000e4;</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Mikkola</surname>
                  <given-names>TS</given-names>
                </name>
                <name name-style="western">
                  <surname>Ropponen</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Ylikorkala</surname>
                  <given-names>O</given-names>
                </name>
              </person-group>
              <article-title>Effect of oral and transdermal hormone therapy on hyaluronic acid in women with and without a history of intrahepatic cholestasis of pregnancy.</article-title>
              <source>Am J Obstet Gynecol</source>
              <year>2008</year>
              <volume>198</volume>
              <fpage>375.e1</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(20 women with and 20 without a history of cholestasis of pregnancy were treated with transdermal contraceptive estrogens and progestins; no patient developed liver test abnormalities, jaundice or itching).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18279829</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.bakry.2008.1">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bakry</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Merhi</surname>
                  <given-names>ZO</given-names>
                </name>
                <name name-style="western">
                  <surname>Scalise</surname>
                  <given-names>TJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Mahmoud</surname>
                  <given-names>MS</given-names>
                </name>
                <name name-style="western">
                  <surname>Fadiel</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Naftolin</surname>
                  <given-names>F</given-names>
                </name>
              </person-group>
              <article-title>Depot-medroxyprogesterone acetate: an update.</article-title>
              <source>Arch Gynecol Obstet</source>
              <year>2008</year>
              <volume>278</volume>
              <fpage>1</fpage>
              <lpage>12</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the chemistry, mechanism of action, clinical efficacy and safety of medroxyprogesterone states: "Very few studies have evaluated the possibility of hepatotoxicity using Depo-Provera").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18470526</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, 2 cases were attributed to an estrogen containing preparation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.franco_hidalgo.2009.72">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Franco Hidalgo</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Prieto de Paula</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Salado Valdivieso</surname>
                  <given-names>I</given-names>
                </name>
              </person-group>
              <comment>[Toxic hepatitis associated with the use of medroxyprogesterone]</comment>
              <source>Gastroenterol Hepatol</source>
              <year>2009</year>
              <volume>32</volume>
              <fpage>72</fpage>
              <lpage>3</lpage>
              <comment>Spanish.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(24 year old woman developed ALT elevations without symptoms 8 days after starting medroxyprogesterone [ALT 1062 U/L, bilirubin and Alk P not provided], which fell to normal within 3 weeks of stopping; identified 13 cases of hepatotoxicity from progesterone in French and Spanish registries, characterized mostly as aminotransferase elevations without jaundice).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19174109</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.ferrajolo.2010.721">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ferrajolo</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Capuano</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Verhamme</surname>
                  <given-names>KM</given-names>
                </name>
                <name name-style="western">
                  <surname>Schuemie</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rossi</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Stricker</surname>
                  <given-names>BH</given-names>
                </name>
                <name name-style="western">
                  <surname>Sturkenboom</surname>
                  <given-names>MC</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2010</year>
              <volume>70</volume>
              <fpage>721</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, ethinylestradiol with levonorgestrel accounted for 43 cases [ranking 27th], with an adjusted odds ratio of 1.9 compared to controls).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21039766</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.devarbhavi.2010.2396">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Devarbhavi</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Dierkhising</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Kremers</surname>
                  <given-names>WK</given-names>
                </name>
                <name name-style="western">
                  <surname>Sandeep</surname>
                  <given-names>MS</given-names>
                </name>
                <name name-style="western">
                  <surname>Karanth</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Adarsh</surname>
                  <given-names>CK</given-names>
                </name>
              </person-group>
              <article-title>Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality.</article-title>
              <source>Am J Gastroenterol</source>
              <year>2010</year>
              <volume>105</volume>
              <fpage>2396</fpage>
              <lpage>404</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 313 cases of drug induced liver injury seen between 1997 and 2008 at a large hospital in Bangalore, India, 1 case was attributed to an OCC).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20648003</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.elouni.2010.2035">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Elouni</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Ben Salem</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Zamy</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Ganne</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Beaugrand</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Bouraoui</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Biour</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports.</article-title>
              <source>Ann Pharmacother</source>
              <year>2010</year>
              <volume>44</volume>
              <fpage>2035</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Two women, ages 28 and 29, developed marked ALT elevations with no jaundice or Alk P elevations 11 and 8 months after starting OCCs, ALT levels increasing [from 7 to 31 times ULN and from 2 to 23 times ULN] as long as OCCs were continued, and resolving within 3-4 weeks once stopped).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21119102</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.winner.2012.1998">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Winner</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Peipert</surname>
                  <given-names>JF</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>Q</given-names>
                </name>
                <name name-style="western">
                  <surname>Buckel</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Madden</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Allsworth</surname>
                  <given-names>JE</given-names>
                </name>
                <name name-style="western">
                  <surname>Secura</surname>
                  <given-names>GM</given-names>
                </name>
              </person-group>
              <article-title>Effectiveness of long-acting reversible contraception.</article-title>
              <source>N Engl J Med</source>
              <year>2012</year>
              <volume>366</volume>
              <fpage>1998</fpage>
              <lpage>2007</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 7486 women receiving reversible contraception followed for up to 5 years, there were 334 unintended pregnancies [4.55 per 100 women-years] and rates were lower with IUDs or implants than with OCC, patch or ring; adverse events were not discussed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22621627</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.nelson.2013.1205">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Nelson</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Apter</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Hauck</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Schmelter</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Rybowski</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Rosen</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Gemzell-Danielsson</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial.</article-title>
              <source>Obstet Gynecol</source>
              <year>2013</year>
              <volume>122</volume>
              <fpage>1205</fpage>
              <lpage>13</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 2,885 women randomized to receive one of two levonorgestrel releasing IUDs, pregnancy rates were similar [0.33 vs 0.31] as were adverse events; no mention of ALT elevations, jaundice or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24240244</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Bergmann</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kvaran</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Olafsson</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none of the 96 were attributed to estrogens or OCCs).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>RA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Summary of 176 published cases of drug induced liver injury from 9 South American countries implicated a total of 53 drugs, 4 cases being due to estrogens, progestins or birth control pills, all of which were from Chile).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 3 [0.3%] were attributed to oral contraceptives and one to estrogen).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.eisenberg.2015.10">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Eisenberg</surname>
                  <given-names>DL</given-names>
                </name>
                <name name-style="western">
                  <surname>Schreiber</surname>
                  <given-names>CA</given-names>
                </name>
                <name name-style="western">
                  <surname>Turok</surname>
                  <given-names>DK</given-names>
                </name>
                <name name-style="western">
                  <surname>Teal</surname>
                  <given-names>SB</given-names>
                </name>
                <name name-style="western">
                  <surname>Westhoff</surname>
                  <given-names>CL</given-names>
                </name>
                <name name-style="western">
                  <surname>Creinin</surname>
                  <given-names>MD</given-names>
                </name>
                <collab>ACCESS IUS Investigators</collab>
              </person-group>
              <article-title>Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.</article-title>
              <source>Contraception</source>
              <year>2015</year>
              <volume>92</volume>
              <fpage>10</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1751 women given a levonorgestrel-releasing IUD the accumulative pregnancy rate was 0.55 [6 pregnancies, 4 ectopic] and adverse events most commonly resulting in discontinuation were expulsion, bleeding, acne and mood swings; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25934164</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.loulergue.2015.258">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Loulergue</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Coriat</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Mir</surname>
                  <given-names>O</given-names>
                </name>
              </person-group>
              <article-title>Recurrent transaminitis induced by oral contraceptives during HIV infection.</article-title>
              <source>Ann Pharmacother</source>
              <year>2015</year>
              <volume>49</volume>
              <fpage>258</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(45 year old woman with HIV infection on a successful antiretroviral regimen developed abnormal liver tests 1 month after starting OCC [levonorgestrel/ethinyl estradiol: 150/30 mcg], with normal bilirubin and Alk P but ALT 17 times ULN, resolving within a month of stopping and 2 years later developed a similar syndrome [ALT 12 times ULN] 2 weeks after starting another OCC [norgestrel/ethinyl estradiol: 500/50 mcg], resolving within 1 month of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25583940</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.choudhary.2017.266">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Choudhary</surname>
                  <given-names>NS</given-names>
                </name>
                <name name-style="western">
                  <surname>Bodh</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Chaudhari</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Saraf</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Saigal</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Norethisterone related drug induced liver injury: a series of 3 cases.</article-title>
              <source>J Clin Exp Hepatol</source>
              <year>2017</year>
              <volume>7</volume>
              <fpage>266</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(3 women with vaginal bleeding, ages 27, 43 and 52 years, were found to have marked serum aminotransferase elevations without symptoms or jaundice 3 weeks to 2 months after starting norethisterone [bilirubin 0.2-1.0 mg/dL, ALT 614-1122 U/L, Alk P 89-151 U/L], improving promptly with discontinuation and recurring with rechallenge in one patient).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28970715</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.cheema.2017.742">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cheema</surname>
                  <given-names>HI</given-names>
                </name>
                <name name-style="western">
                  <surname>Gupta</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Levonorgestrel-releasing intrauterine device-related acute liver injury.</article-title>
              <source>Case Rep Gastroenterol</source>
              <year>2017</year>
              <volume>11</volume>
              <fpage>742</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(24 year old woman developed abdominal pain 2 months after insertion of levonorgestrel-releasing IUD [bilirubin 11.2 mg/dL, ALT 3,243 U/L, Alk P 166 U/L], which resolved within 60 days of withdrawal of the IUD).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29430227</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF38">
            <element-citation publication-type="journal">
              <article-title>Choice of contraceptives.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2018</year>
              <volume>60</volume>
              <issue>1557</issue>
              <fpage>161</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review of the efficacy and tolerance of currently available of contraceptives concludes that intrauterine devices and etonogestrel implants are the most effective reversible contraceptive methods; no discussion of hepatic adverse events).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30335731</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.stannov.2019.322">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Stannov</surname>
                  <given-names>SU</given-names>
                </name>
                <name name-style="western">
                  <surname>Ries</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Bang</surname>
                  <given-names>UC</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity induced by a second-generation combined oral contraceptive: case report and review of the literature.</article-title>
              <source>Eur J Contracept Reprod Health Care</source>
              <year>2019</year>
              <volume>24</volume>
              <issue>4</issue>
              <fpage>322</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(24 year old woman developed fatigue and elevated liver tests having been on ethinyl estradiol/levonorgestrel [30/150 mcg] OCC for 2 years, ALT rising from 154 U/L to ~680 U/L with continued OCC use, falling with temporary stopping and rising with restarting, finally falling to normal after discontinuation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30983430</pub-id>
            </element-citation>
          </ref>
          <ref id="Progestins.REF.teal.2019.63">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Teal</surname>
                  <given-names>SB</given-names>
                </name>
                <name name-style="western">
                  <surname>Turok</surname>
                  <given-names>DK</given-names>
                </name>
                <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>BA</given-names>
                </name>
                <name name-style="western">
                  <surname>Kimble</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Olariu</surname>
                  <given-names>AI</given-names>
                </name>
                <name name-style="western">
                  <surname>Creinin</surname>
                  <given-names>MD</given-names>
                </name>
              </person-group>
              <article-title>Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system.</article-title>
              <source>Obstet Gynecol</source>
              <year>2019</year>
              <volume>133</volume>
              <fpage>63</fpage>
              <lpage>70</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1751 women [ages 16 to 45 years] given levonorgestrel intrauterine device, successful placement was achieved in 1714 [98%] and the pregnancy yearly rate was 0.15 to 0.20%, while adverse events included vaginal bacterial and fungal infections, acne, nausea and vomiting, dyspareunia, headache, pelvic pain, breast tenderness, anxiety, depression, mood changes, weight gain and bleeding; no mention of ALT elevations, jaundice or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30531565</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Progestins.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Progestins+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Progestins: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Progestins">Trials on Progestins: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
